Title: Vera Molkenthin: Innovator in Immunotherapy
Introduction
Vera Molkenthin is a notable inventor based in Germany, recognized for her contributions to the field of immunotherapy. With a focus on binding proteins and antibody humanization, her work has significant implications for treating various cancers, particularly acute myeloid leukemia (AML).
Latest Patents
Vera Molkenthin has developed several innovative patents, including:
1. **Bispecific Cd33 And Cd3 Binding Proteins** - This patent describes binding proteins that specifically target human CD33 and CD3. It includes bispecific tandem diabodies that bind to CD33, which are utilized for immunotherapy in treating CD33+ cancers and diseases.
2. **Method For Mass Humanization Of Rabbit Antibodies** - This invention outlines a method for producing a population of nucleic acids encoding proteins with rabbit-derived CDR3 amino acid sequences embedded in human framework sequences. This method has potential applications in creating humanized antibodies for therapeutic use.
Career Highlights
Throughout her career, Vera has worked with several prominent companies, including Affimed Therapeutics and Abcheck S.r.o. Her experience in these organizations has allowed her to advance her research and contribute to the development of innovative therapies.
Collaborations
Vera has collaborated with notable professionals in her field, including Kristina Ellwanger and Uwe Reusch. These partnerships have fostered a collaborative environment that enhances the potential for groundbreaking discoveries in immunotherapy.
Conclusion
Vera Molkenthin's work in the field of immunotherapy exemplifies her commitment to advancing medical science through innovation. Her patents and collaborations highlight her significant contributions to the treatment of cancers, paving the way for future advancements in the field.